Adverum Biotechnologies Inc. (ADVM) and ChemoCentryx Inc. (NASDAQ:CCXI) Comparison side by side

Adverum Biotechnologies Inc. (NASDAQ:ADVM) and ChemoCentryx Inc. (NASDAQ:CCXI), both competing one another are Biotechnology companies. We will contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adverum Biotechnologies Inc. 8 531.67 N/A -1.12 0.00
ChemoCentryx Inc. 11 12.25 N/A -0.80 0.00

Table 1 demonstrates Adverum Biotechnologies Inc. and ChemoCentryx Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us Adverum Biotechnologies Inc. and ChemoCentryx Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Adverum Biotechnologies Inc. 0.00% -33.4% -30.8%
ChemoCentryx Inc. 0.00% -111.1% -19.7%

Volatility and Risk

A beta of 2.43 shows that Adverum Biotechnologies Inc. is 143.00% more volatile than S&P 500. ChemoCentryx Inc.’s 3.00% more volatile than S&P 500 volatility due to the company’s 1.03 beta.

Liquidity

18.2 and 18.2 are the respective Current Ratio and a Quick Ratio of Adverum Biotechnologies Inc. Its rival ChemoCentryx Inc.’s Current and Quick Ratios are 3.4 and 3.4 respectively. Adverum Biotechnologies Inc. has a better chance of clearing its pay short and long-term debts than ChemoCentryx Inc.

Analyst Ratings

The table shown features the ratings and recommendations for Adverum Biotechnologies Inc. and ChemoCentryx Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Adverum Biotechnologies Inc. 0 0 0 0.00
ChemoCentryx Inc. 0 0 4 3.00

ChemoCentryx Inc. on the other hand boasts of a $22.25 consensus target price and a 222.00% potential upside.

Insider and Institutional Ownership

Roughly 76% of Adverum Biotechnologies Inc. shares are held by institutional investors while 59.6% of ChemoCentryx Inc. are owned by institutional investors. About 11.22% of Adverum Biotechnologies Inc.’s share are held by insiders. On the other hand, insiders held about 4.9% of ChemoCentryx Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Adverum Biotechnologies Inc. -8.28% 15.9% 106.94% 342.57% 185.32% 325.71%
ChemoCentryx Inc. 0.25% -10.94% -38.33% -35.49% -28.17% -26.86%

For the past year Adverum Biotechnologies Inc. had bullish trend while ChemoCentryx Inc. had bearish trend.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.